Trade Names:Pyrlex- Suspension 12 mg per 5 mL
Suppresses symptoms of allergic rhinitis.
Symptomatic relief of acute rhinitis and nasal congestion associated with the common cold, seasonal and perennial allergic rhinitis, sinusitis, and other respiratory tract conditions.
Newborns; breast-feeding women; hypersensitivity.
PO 12 to 24 mg (5 to 10 mL) every 12 h (max, 48 mg per 24 h).Children 6 to 12 yr of age
PO 12 mg (5 mL) every 12 h (max, 24 mg per 24 h).Children 2 to 6 yr of age
PO 6 mg (2.5 mL) every 12 h (max, 12 mg per 24 h).
Store at 59° to 86°F. Protect from light and freezing.
May have additive CNS effects (eg, increased drowsiness).Antihypertensives (eg, mecamylamine, methyldopa, reserpine, veratrum alkaloids)
Antihypertensive effects may be reduced.Beta-blockers (eg, propranolol)
Effects of pyrilamine may be increased.MAOIs
Do not use with or within 14 days after stopping MAOI therapy.Sympathomimetics
Increased risk of mild sedation or stimulation.
None well documented.
CNS depression, drowsiness, sedation.
Dryness of mucous membranes.
Urinary retention in patients with prostatic hypertrophy.
Monitor renal function in elderly patients.
Category C .
Safety and efficacy not established in children younger than 2 yr of age.
Use with caution because of increased likelihood of decreased renal function, increasing the risk of dizziness, hypertension, and sedation.
Risk of toxicity may be increased in patients with renal function impairment.
Use with caution in patients with CV disease, diabetes, hypertension, hyperthyroidism, narrow-angle glaucoma, or prostatic hypertrophy.
May cause excitation, particularly in children.
Atropine-like signs and symptoms, CNS stimulation or depression. CNS depression, convulsions, death, diminished mental alertness, excitation, hallucinations, or respiratory or cardiac arrest in infants and children.
Copyright © 2009 Wolters Kluwer Health.